12-Month Lobbying Summary - In-house Corporation

• Subject matter details in previous versions

  Details Regarding the Identified Subject Matter

  Subject matters	Details	Categories
  Subject matters were not required to be associated with subject matter details when this content was submitted	Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food and Drug Act.	Legislative Proposal, Bill or Resolution
  Subject matters were not required to be associated with subject matter details when this content was submitted	Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly Canada's business	Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention.	Legislative Proposal, Bill or Resolution
  Subject matters were not required to be associated with subject matter details when this content was submitted	Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry.	Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Patented Medicines Pricing Review Board (PMPRB) – regulations that can impact the Canadian pharmaceutical industry.	Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	The government's Science and Technology Strategy potential policies and programs pertaining to the biopharmaceutical industry	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry	Policies or Program

  Subject matters in previous versions

  • Economic Development
  • Health
  • Industry
  • Intellectual Property
  • International Trade
  • Research and Development
  • Science and Technology
  • Taxation and Finance

Government Institutions

• Agriculture and Agri-Food Canada (AAFC)
• Federal Economic Development Agency for Southern Ontario (FedDev)
• Finance Canada (FIN)
• Global Affairs Canada (GAC)
• Great Lakes Pilotage Authority
• Health Canada (HC)
• House of Commons
• Innovation, Science and Economic Development Canada (ISED)
• Invest in Canada Hub
• Patented Medicine Prices Review Board (PMPRB)
• Prime Minister's Office (PMO)
• Privy Council Office (PCO)
• Public Health Agency of Canada (PHAC)
• Senate of Canada
• Treasury Board Of Canada Secretariat (TBS)

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

• Written communication
• Oral communication
• Arrange one or more meetings

Senior Officers whose lobbying activities represent less than 20% of their Duties

• Kenneth L Custer, President and General Manager | No public offices held
• Jill Daley, General Counsel & Vice-President Corporate Affairs | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

• Christopher Praught, Sr. Manager, Policy & Government Relations, Corporate Affairs | Designated public offices held